Professor Sunil Shaunak

Publications


Journals

  • Morris TC; Moore LS; Shaunak S. (2012). Doctors taking a pulse using their mobile phone can spread MRSA. BMJ. 344:e412.
  • Barata TS; Brocchini S; Teo I; Shaunak S; Zloh M. (Nov 2011). From sequence to 3D structure of hyperbranched molecules: application to surface modified PAMAM dendrimers. J Mol Model. 17:2741-2749. DOI.
  • Barata T; Teo I; Lalwani S; Simanek E; Zloh M; Shaunak S. (Nov 2011). Computational design principles for bioactive dendrimer based constructs as antagonists of the TLR4-MD-2-LPS complex. Biomaterials. 32:8702-8711. DOI.
  • Barata TS; Shaunak S; Teo I; Zloh M; Brocchini S. (Aug 2011). Structural studies of biologically active glycosylated polyamidoamine (PAMAM) dendrimers. J Mol Model. 17:2051-2060. DOI.
  • Corware K; Harris D; Teo I; Rogers M; Naresh K; Müller I; Shaunak S. (Nov 2011). Accelerated healing of cutaneous leishmaniasis in non-healing BALB/c mice using water soluble amphotericin B-polymethacrylic acid. Biomaterials. 32:8029-8039. DOI.
  • Barata TS; Teo I; Brocchini S; Zloh M; Shaunak S. (Jun 2011). Partially glycosylated dendrimers block MD-2 and prevent TLR4-MD-2-LPS complex mediated cytokine responses. PLoS Comput Biol. 7:e1002095. DOI.
  • Barata TS; Brocchini S; Teo I; Shaunak S; Zloh M. (Oct 2010). Structural Studies on Glycosylated PAMAM Dendrimers. J PHARM PHARMACOL. 62:1371-1372.
  • Corware KD; Rogers M; Teo I; Müller I; Shaunak S. (Nov 2010). An amphotericin B-based drug for treating experimental Leishmania major infection. Trans R Soc Trop Med Hyg. 104:749-750. DOI.
  • Armstrong-James D; Teo IA; Shrivastava S; Petrou MA; Taube D; Dorling A; Shaunak S. (Aug 2010). Exogenous interferon-gamma immunotherapy for invasive fungal infections in kidney transplant patients. Am J Transplant. 10:1796-1803. DOI.
  • Lalwani S; Chouai A; Perez LM; Santiago V; Shaunak S; Simanek EE. (8 Sep 2009). Mimicking PAMAM Dendrimers with Amphoteric, Hybrid Triazine Dendrimers: A Comparison of Dispersity and Stability. MACROMOLECULES. 42:6723-6732. DOI.
  • Lalwani S; Venditto VJ; Chouai A; Rivera GE; Shaunak S; Simanek EE. (28 Apr 2009). Electrophoretic Behavior of Anionic Triazine and PAMAM Dendrimers: Methods for Improving Resolution and Assessing Purity Using Capillary Electrophoresis. MACROMOLECULES. 42:3152-3161. DOI.
  • Zloh M; Shaunak S; Balan S; Brocchini S. (2007). Identification and insertion of 3-carbon bridges in protein disulfide bonds: a computational approach. NAT PROTOC. 2:1070-1083. DOI.
  • Brocchini S; Godwin A; Balan S; Choi JW; Zloh M; Shaunak S. (3 Jan 2008). Disulfide bridge based PEGylation of proteins. ADV DRUG DELIVER REV. 60:3-12. DOI.
  • Brocchini S; Balan S; Godwin A; Choi JW; Zloh M; Shaunak S. (2006). PEGylation of native disulfide bonds in proteins. NAT PROTOC. 1:2241-2252. DOI.
  • Shaunak S; Brocchini S. (Jun 2007). Entrepreneurial experiences. NAT REV DRUG DISCOV. 6:499-499.
  • Balan S; Choi JW; Godwin A; Teo I; Laborde CM; Heidelberger S; Zloh M; Shaunak S; et alBrocchini S. (Jan 2007). Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge. Bioconjug Chem. 18:61-76. DOI.
  • Steel A; Clark S; Teo I; Shaunak S; Nelson M; Gazzard B; Kelleher P. (1 Aug 2006). No change to HIV-1 latency with valproate therapy. AIDS. 20:1681-1682. DOI.
  • Shaunak S; Godwin A; Choi JW; Balan S; Pedone E; Vijayarangam D; Heidelberger S; Teo I; et alZloh M; Brocchini S. (Jun 2006). Site-specific PEGylation of native disulfide bonds in therapeutic proteins. Nat Chem Biol. 2:312-313. DOI.
  • Summers SA; Dorling A; Boyle JJ; Shaunak S. (Aug 2005). Cure of disseminated cryptococcal infection in a renal allograft recipient after addition of gamma-interferon to anti-fungal therapy. Am J Transplant. 5:2067-2069. DOI.
  • Teo I; Choi JW; Buttigieg K; Shaunak S. (Mar 2005). Pitfalls of culturing C8166 cells in serum-free media. AIDS RES HUM RETROV. 21:246-248.
  • Teo I; Choi JW; Buttigieg K; Shaunak S. (Mar 2005). Short communication: pitfalls of culturing C8166 cells in serum-free media. AIDS Res Hum Retroviruses. 21:246-248. DOI.
  • Shaunak S; Thomas S; Gianasi E; Godwin A; Jones E; Teo I; Mireskandari K; Luthert P; et alDuncan R; Patterson S; Khaw P; Brocchini S. (Aug 2004). Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation. Nat Biotechnol. 22:977-984. DOI.
  • Shaunak S; Teo I. (Dec 2003). Monitoring HIV disease with new and clinically useful surrogate markers. Curr Opin Infect Dis. 16:581-586. DOI.
  • Shaunak S; Teo I; Choi JW; Gazzard B. (17 Oct 2003). HIV DNA two long terminal repeat circles: observations and interpretations. AIDS. 17:2273-2274. DOI.
  • Shaunak S; Thornton M; Teo I; Chandler B; Jones M; Steel S. (Aug 2003). Optimisation of the degree of sulfation of a polymer based construct to block the entry of HIV-1 into cells. J Drug Target. 11:443-448. DOI.
  • Stebbing J; Gazzard B; Kim L; Portsmouth S; Wildfire A; Teo I; Nelson M; Bower M; et alGotch F; Shaunak S; Srivastava P; Patterson S. (15 May 2003). The heat-shock protein receptor CD91 is up-regulated in monocytes of HIV-1-infected "true" long-term nonprogressors. Blood. 101:4000-4004. DOI.
  • Morlese J; Teo IA; Choi JW; Gazzard B; Shaunak S. (28 Mar 2003). Identification of two mutually exclusive groups after long-term monitoring of HIV DNA 2-LTR circle copy number in patients on HAART. AIDS. 17:679-683. DOI.
  • Teo IA; Choi JW; Morlese J; Taylor G; Shaunak S. (1 Dec 2002). LightCycler qPCR optimisation for low copy number target DNA. J Immunol Methods. 270:119-133.
  • Teo IA; Morlese J; Choi JW; Shaunak S. (1 Dec 2002). Reliable and reproducible LightCycler qPCR for HIV-1 DNA 2-LTR circles. J Immunol Methods. 270:109-118.
  • Shaunak S; Davies DS. (Jul 2002). Surrogacy in antiviral drug development. Br J Clin Pharmacol. 54:75-80.
  • Vyakarnam A; Eyeson J; Teo I; Zuckerman M; Babaahmady K; Schuitemaker H; Shaunak S; Rostron T; et alRowland-Jones S; Simmons G; Clapham P. (7 Sep 2001). Evidence for a post-entry barrier to R5 HIV-1 infection of CD4 memory T cells. AIDS. 15:1613-1626.
  • Shaunak S; Veryard C; Javan C. (Jul 2001). Severe Pneumocystis carinii pneumonia increases the infectious titre of HIV-1 in blood and can promote the expansion of viral chemokine co-receptor tropism. J Infect. 43:3-6. DOI.
  • Kelleher AD; Long C; Holmes EC; Allen RL; Wilson J; Conlon C; Workman C; Shaunak S; et alOlson K; Goulder P; Brander C; Ogg G; Sullivan JS; Dyer W; Jones I; McMichael AJ; Rowland-Jones S; Phillips RE. (5 Feb 2001). Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J Exp Med. 193:375-386.
  • Kelleher AD; Long C; Holmes EC; Allen RL; Wilson J; Conlon C; Workman C; Shaunak S; et alOlson K; Goulder P; Brander C; Ogg G; Sullivan JS; Dyer W; Jones I; McMichael AJ; Rowland-Jones S; Phillips RE. (5 Feb 2001). Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J EXP MED. 193:375-385.
  • Veryard C; Javan C; Shaunak S. (22 Dec 2000). Repeated and spontaneous switching of the chemokine co-receptors used by HIV-1 is rare in vivo. AIDS. 14:2942-2943.
  • Leen C; Shaunak S; Steinhart C; SAINT TITAN ATLAS Study Investiga. (Oct 2000). Tolerability of a novel approach to salvage therapy for AIDS. AIDS. 14:S39-S40.
  • Wilson JDK; Ogg GS; Allen RL; Davis C; Shaunak S; Downie J; Dyer W; Workman C; et alSullivan JS; McMichael AJ; Rowland-Jones SL. (18 Feb 2000). Direct visualization of HIV-1-specific cytotoxic T lymphocytes during primary infection. AIDS. 14:225-233.
  • Pickering MC; Barkham T; Mason JC; Shaunak S; Davies KA. (Feb 2000). Bilateral gluteal abscesses as a unique manifestation of Fusobacterium septicaemia. RHEUMATOLOGY. 39:224-225.
  • Sharkey ME; Teo I; Greenough T; Sharova N; Luzuriaga K; Sullivan JL; Bucy RP; Kostrikis LG; et alHaase A; Veryard C; Davaro RE; Cheeseman SH; Daly JS; Bova C; Ellison RT; Mady B; Lai KK; Moyle G; Nelson M; Gazzard B; Shaunak S; Stevenson M. (Jan 2000). Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med. 6:76-81. DOI.
  • Marcus CD; Taylor-Robinson SD; Cox IJ; Sargentoni J; Shaunak S. (Dec 1999). Reversible alterations in brain metabolites during therapy for disseminated nocardiosis using proton magnetic resonance spectroscopy. Metab Brain Dis. 14:231-237.
  • Thornton M; Barkley L; Mason JC; Shaunak S. (Oct 1999). Anti-Kaposi's sarcoma and antiangiogenic activities of sulfated dextrins. Antimicrob Agents Chemother. 43:2528-2533.
  • Marcus CD; Taylor-Robinson SD; Sargentoni J; Ainsworth JG; Frize G; Easterbrook PJ; Shaunak S; Bryant DJ. (Jun 1998). 1H MR spectroscopy of the brain in HIV-1-seropositive subjects: evidence for diffuse metabolic abnormalities. Metab Brain Dis. 13:123-136.
  • Shaunak S; Thornton M; John S; Teo I; Peers E; Mason P; Krausz T; Davies DS. (5 Mar 1998). Reduction of the viral load of HIV-1 after the intraperitoneal administration of dextrin 2-sulphate in patients with AIDS. AIDS. 12:399-409.
  • Ogg G; Lynn WA; Peters M; Curati W; McLaughlin JE; Shaunak S. (Nov 1997). Cerebral nocardia abscesses in a patient with AIDS: correlation of magnetic resonance and white cell scanning images with neuropathological findings. J Infect. 35:311-313.
  • Smith S; Robinson J; Hollyer J; Bhatt R; Ash S; Shaunak S. (17 Feb 1996). Combining specialist and primary health care teams for HIV positive patients: retrospective and prospective studies. BMJ. 312:416-420.
  • SABROE I; MCHALE J; TAIT DR; LYNN WA; WARD KN; SHAUNAK S. (Nov 1995). TREATMENT OF ADENOVIRAL PNEUMONITIS WITH INTRAVENOUS RIBAVIRIN AND IMMUNOGLOBULIN. THORAX. 50:1219-1220.
  • SABROE I; BLOOM S; HUGHES JMB; SHAUNAK S; ROBERTSON I; LYNN WA. (26 Aug 1995). GRAND ROUNDS - HAMMERSMITH-HOSPITAL - THROMBOEMBOLIC OCCLUSION OF A PULMONARY ARTERIOVENOUS MALFORMATION - A VERY UNUSUAL PULMONARY-EMBOLISM. BRIT MED J. 311:553-555.
  • SHAUNAK S. (Mar 1995). A CASE OF ACINETOBACTER-CALCOACETICUS PNEUMONIA - COMMENTARY. THORAX. 50:317-318.
  • SHAUNAK S; COHEN J. (Sep 1994). LACK OF TOXICITY OF LONG-TERM, HIGH TOTAL-DOSE LIPOSOMAL AMPHOTERICIN-B. J ANTIMICROB CHEMOTH. 34:451-452.
  • SRISKANDAN S; SHAUNAK S. (Dec 1993). RESPIRATORY SYNCYTIAL VIRUS-INFECTION IN AN ADULT WITH AIDS. CLIN INFECT DIS. 17:1065-1065.
  • SMITH S; PARKER C; SHAUNAK S; ASH S; BHATT R. (25 Sep 1993). FUNDING POLICIES FOR HIV AND AIDS - GPS SHOULD BE MORE INVOLVED. BRIT MED J. 307:801-802.
  • Shaunak S; Weber JN. (Apr 1992). The retroviruses: classification and molecular biology. Baillieres Clin Neurol. 1:1-21.
  • Cheingsong-Popov R; Callow D; Beddows S; Shaunak S; Wasi C; Kaleebu P; Gilks C; Petrascu IV; et alGaraev MM; Watts DM. (Feb 1992). Geographic diversity of human immunodeficiency virus type 1: serologic reactivity to env epitopes and relationship to neutralization. J Infect Dis. 165:256-261.
  • SHAUNAK S. (23 Jan 1992). PULMONARY TUBERCULOSIS AND HIV-INFECTION. BRIT J HOSP MED. 47:151-151.
  • SHAUNAK S; COHEN J. (Jul 1991). CLINICAL MANAGEMENT OF FUNGAL INFECTION IN PATIENTS WITH AIDS. J ANTIMICROB CHEMOTH. 28:67-81.
  • Shaunak S; Cohen J. (Jul 1991). Clinical management of fungal infection in patients with AIDS. J Antimicrob Chemother. 28 Suppl A:67-82.
  • SHAUNAK S. (Dec 1989). MCQS ON HIV INFECTION. BRIT J HOSP MED. 42:A501-A502.
  • SHAUNAK S; WENDON J; MONTEIL M; GORDON AM. (Nov 1988). SEPTIC SCARLET FEVER DUE TO STREPTOCOCCUS-PYOGENES CELLULITIS. Q J MED. 69:921-925.
  • Shaunak S; Munro JM; Weinbren K; Walport MJ; Cox TM. (Apr 1988). Cyclophosphamide-induced liver necrosis: a possible interaction with azathioprine. Q J Med. 67:309-317.
  • JAYNE DRW; JONES SJ; LOCKWOOD CM; SEVERN A; SHAUNAK S; MURPHY J. (1987). SEVERE PULMONARY HEMORRHAGE AND SYSTEMIC VASCULITIS IN ASSOCIATION WITH CIRCULATING IGM ANTINEUTROPHIL ANTIBODY. CLIN SCI. 73:P27-P27.

Chapters in books

  • Shaunak S. Dendrimer drugs prevent scar tissue formation. In Discovery Medicine. 464-469. Rose NR (ed). Peter H. Rheinstein (2004).
  • Shaunak S. HIV and its manipulation of chemokine receptors. In Postgraduate Medical Sciences Series. Infection and Immunity. 177-190. Friedland JS (ed); Lightstone LB (ed). Martin Dunitz Publishers (2003).

Conferences

  • Monnery B; Shaunak S; Thanou M; Steinke JHG. Monodisperse 1-PEI: A route to the optimum polymer transfectant?. 22:A90-A91. (Oct 2011).
  • Thornton M; Krausz T; Shaunak S. Tissue macrophages release MIP-1 alpha and MIP-1 beta but not TNF-alpha, IL-4, IL-6 or IFN-gamma after the internalisation of dextrin 2-sulphate. 183-188. (1999).
  • Godwin A; Choi JW; Pedone E; Balan S; Jumnah R; Shaunak S; Brocchini S; Zloh M. Molecular dynamics simulations of proteins with chemically modified disulfide bonds. 10th Electronic Computational Chemistry Conference. 117:259-265. (Feb 2007).
  • Jones E; Mireskandari K; Mead A; Thomas S; Luthert P; Brocchini S; Shaunak S; Khaw PT. The effect of novel immuno-modulatory and anti-angiogenic glycodendrimers in a rabbit model of glaucoma surgery. 45:U392-U392. (Apr 2004).
  • Teo I; Choi JW; Shaunak S. Macrophage cell cultures continue to produce infectious HIV-1 long after acute cytopathic infection has subsided. 4th European Conference on Experimental AIDS Research. 177-181. (1999).
  • Shaunak S; Waterworth C; Lynn WA. Targeting HIV-1 replication in gut-associated lymphoid tissue. 4th European Conference on Experimental AIDS Research. 163-166. (1999).

Patents

  • Antiviral agent comprising CD4 and an H2 histone. Patent number: WO 9321943A1.
  • Complexes having adjuvant activity. Patent number: WO 005065712A2.
  • Conjugated biological molecules and their preparation. Patent number: W0 05007197A2.
  • Glyco-dendrimers having biological activity. Patent number: W0 03089010A1.
  • Treatment of angiogenesis dependent conditions. Patent number: WO 107057A1.
  • Treatment of highly vascular tumours. Patent number: WO 9824421A2.
Share this on DeliciousTweet thisDigg thisStumble thisShare this on Facebook